HAIFA, Israel , August 13 /PRNewswire/ -- SCD has announced the receipt of a phase I contract from DARPA, valued at $1.75 million, for the development of a new "XBn" infrared detector technology. If ...
Enables standardized inpatient hospital billing for QUELIMMUNE® (SCD-PED) therapy Universal code paves the way for billing of ...
DENVER, April 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients ...
SeaStar Medical Holding Corporation (NASDAQ:ICU) shares are trading higher on Thursday, on continued strength after the company received FDA Breakthrough Device Designation for its cell-directed ...
FDA approves SeaStar Medical's SCD-ADULT study for treating acute heart failure with renal issues, funded by a $3.6 million NIH grant. SeaStar Medical Holding Corporation announced that the U.S. FDA ...
Interim study data show that SCD treatment is safe to use in pediatric patients with Acute Kidney Injury (AKI) requiring continuous kidney replacement therapy (CKRT) The SCD is currently being ...
DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...
Application of the immunomodulatory selective cytopheretic device (SCD) to enhance renal replacement therapy and improve outcomes of acute kidney injury in pediatric patients is impeded by safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results